Key Takeaways Ionis Pharmaceuticals secures FDA priority review for zilganersen to treat rare Alexander disease.FDA grants priority review as a phase III study shows significant stabilization in patients' gait speed. IONS said the FDA set a target action date of Sept. 22, 2026, for the NDA decision.Ionis Pharmaceuticals (IONS) announced that the FDA has granted priority review to its new drug application (NDA) seeking approval for zilganersen for the treatment of patients with Alexander disease (AxD), a rar ...

Core Insights - Ionis Pharmaceuticals is entering a pivotal phase in 2025, transitioning into a fully integrated commercial-stage biotechnology company with strong initial launches of TRYNGOLZA and DAWNZERA [1][4] Commercial Performance - TRYNGOLZA generated $108 million in its first year, with a 56% quarter-over-quarter revenue increase, leading to raised peak sales expectations for the combined FCS/sHTG opportunity to over $2 billion [5][10] - DAWNZERA is positioned as the first RNA-targeted medicine for hereditary angioedema (HAE) prevention, resonating well with physicians and patients [11] Product Launch and Pipeline - The FDA accepted Ionis' supplemental NDA for olezarsen in severe hypertriglyceridemia (sHTG) with a priority review and a PDUFA date of June 30, positioning the company for a launch at the end of June or early July [4][6] - Ionis anticipates three product approvals and launches in 2026, including olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for chronic hepatitis B [5][8] Market Opportunity - The sHTG market is significant, affecting over 3 million people in the U.S., with an estimated 1 million high-risk patients eligible for olezarsen [8] - The initial launch focus for sHTG will target high-risk patients with triglycerides above 500 and those above 880, based on feedback from medical specialists [12] Financial Guidance - The priority review for olezarsen is expected to accelerate market entry by four months, leading to improved financial guidance, which will be updated during the end-of-first-quarter earnings call [13] Neurology Pipeline - Ionis is advancing its neurology franchise with the upcoming launch of zilganersen for Alexander disease, supported by positive phase III data [14] - The phase III program for obinutersen in Angelman syndrome is ongoing, with enrollment expected to complete this year [15]

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: FY Conference Call on February 26, 2026 - **Key Speaker**: Brett Monia, CEO Core Industry and Company Insights - **FDA Acceptance**: The FDA accepted the supplemental NDA for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review status, setting a PDUFA date of June 30, 2026, which positions the company for a launch in late June or early July [2][3] - **Transformational Year**: 2025 was described as a pivotal year for Ionis, marking its transition to a fully integrated commercial-stage biotechnology company with successful independent launches of TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) [3][4] - **Revenue Growth**: The company aims to achieve cash flow break-even by 2028, with expectations of accelerating revenue growth driven by its innovative pipeline [4][5] Product Pipeline and Launch Strategy - **Pipeline Success**: Ionis has had six positive Phase 3 readouts and four approved medicines in the last two and a half years, with 11 medicines in late-stage development [6][7] - **Upcoming Launches**: Expected product approvals and launches in 2026 include: - Olezarsen for sHTG - Zilganersen for Alexander disease - Bepirovirsen for chronic HBV [7][8] - **Market Focus**: Initial launch strategy for sHTG will prioritize patients with a history of acute pancreatitis and those with triglyceride levels above 880, as these patients are at the highest risk [29][30] Financial Projections - **Revenue Guidance**: The acceptance of the priority review for olezarsen is expected to improve revenue guidance, with updates to be provided in the Q1 earnings call [32] - **Peak Product Revenue**: The company anticipates over $4 billion in potential annual peak product revenue from its own medicines, with an additional $2 billion from partnered medicines, totaling over $6 billion in revenue [20][21] Neurology Portfolio - **Zilganersen Launch**: Zilganersen is positioned as Ionis' first independent launch in neurology, with positive Phase 3 data reported and an NDA submitted [19][36] - **Future Developments**: The company is also working on the Angelman syndrome program, which has received Breakthrough Therapy designation and is expected to complete enrollment in its Phase III study this year [20][39] Competitive Landscape and Innovation - **DAWNZERA's Competitive Edge**: DAWNZERA is noted for its compelling product profile, offering better efficacy, tolerability, and convenience compared to existing treatments for HAE [11][12] - **Follow-On Programs**: Ionis is exploring follow-on programs for its existing products to enhance dosing convenience and efficacy [33][34] Conclusion - **Outlook**: Ionis Pharmaceuticals is positioned for a transformative year in 2026, with multiple product launches and a strong pipeline that addresses significant unmet medical needs in cardiometabolic and neurological diseases [21][42]

Core Insights - Ionis Pharmaceuticals reported an EPS of -$1.41, missing consensus estimates of around -$1.23, but exceeded revenue expectations with $203 million in total revenue [1][3] - The company has shown a pattern of revenue beats in recent quarters despite a year-over-year decline in Q4 total revenue [4] Financial Performance - Ionis reported a total revenue of $203 million for Q4 2025, which is an ~11% decline from $227 million in Q4 2024, but surpassed the Zacks Consensus Estimate by ~30% [3][4] - Commercial revenue grew approximately 64% to ~$141 million in Q4, driven by products like TRYNGOLZA, offsetting declines in royalties and R&D revenue [4] - The current ratio stands at approximately 2.79, indicating good short-term financial health despite ongoing unprofitability [2][5] Valuation Metrics - Ionis has a negative price-to-earnings (P/E) ratio of approximately -50, indicating current unprofitability [5] - The price-to-sales ratio is about 13, suggesting investors are willing to pay a premium for revenue amid pipeline expectations [5] - The enterprise value to sales ratio is also approximately 13, reflecting the company's valuation relative to revenue [5] Future Outlook - Ionis is focused on discovering and developing RNA-targeted therapeutics, with multiple independent launches planned for 2026 [2] - CEO Brett P. Monia emphasized the potential for continued success in 2026, highlighting upcoming launches such as olezarsen for sHTG and zilganersen for AxD [4]

Core Insights - The company has successfully transitioned into a fully integrated commercial-stage entity following the independent launches of TRYNGOLZA and DAWNZERA [1] - TRYNGOLZA's performance was attributed to its compelling clinical profile and strong execution, achieving $108 million in full-year revenue [1] - Breakthrough Phase III results for olezarsen in severe hypertriglyceridemia showed an unprecedented 85% reduction in acute pancreatitis events [1] - Positive Phase III data for zilganersen has strengthened the company's strategic positioning in neurology, marking it as the first therapy to demonstrate disease-modifying benefits in Alexander disease [1] - The company experienced a revenue growth of 34% year-over-year, supported by a diversified model that includes recurring income from marketed medicines and financial accelerators from R&D collaborations [1] - Disciplined investment strategies have allowed the company to exceed financial guidance while expanding its commercial field organization to 200 members [1]

Core Insights - Ionis Pharmaceuticals has successfully executed its first two independent commercial launches, DAWNZERA and TRYNGOLZA, marking a significant year for the company [3] Product Launches - DAWNZERA, approved in August as a prophylactic treatment for hereditary angioedema (HAE), is the first RNA-targeted medicine for HAE, with a peak sales potential exceeding $500 million [1] - TRYNGOLZA, the first FDA-approved treatment for familial chylomicronemia syndrome (FCS), generated fourth-quarter net product sales of $50 million, a 56% increase sequentially, and full-year revenue of $108 million [2][6] Financial Performance - Ionis reported 2025 revenue of $944 million, a 34% year-over-year increase, with 46% from commercial products and 54% from R&D collaborations [12] - The company provided 2026 revenue guidance of $800 million to $825 million, reflecting a one-time $280 million license fee in 2025, indicating approximately 20% underlying growth [4][14] Pipeline Developments - Olezarsen for severe hypertriglyceridemia (sHTG) showed up to a 72% triglyceride reduction and an 85% reduction in acute pancreatitis events, with a supplemental NDA submitted and priority review requested [5][8] - Zilganersen for Alexander disease is anticipated to receive approval in the second half of 2026, with peak revenue guidance exceeding $100 million [9] Commercial Strategy - The company emphasized strong early adoption for DAWNZERA, with a 100% conversion to paid therapy from the free trial program [1] - Management noted that approximately 75% of TRYNGOLZA prescriptions came from specialists, indicating a targeted approach to market penetration [2] Future Outlook - Ionis aims for cash-flow breakeven by 2028, with a projected non-GAAP operating loss of $500 million to $550 million for 2026 [20][21] - The company expects a meaningful decline in TRYNGOLZA revenue during 2026 ahead of the sHTG launch, followed by growth if approval occurs [16]

Financial Data and Key Metrics Changes - In 2025, Ionis Pharmaceuticals generated $944 million in revenue, representing a 34% increase year-over-year [30] - Revenue from commercial products was $436 million (46% of total revenue), while R&D collaborations contributed $508 million (54% of total revenue) [30] - Royalty revenues increased by 11% to $285 million, driven by contributions from Spinraza and Waylivra [32] Business Line Data and Key Metrics Changes - TRYNGOLZA generated $108 million in product sales in 2025, with a 56% increase in Q4 revenues compared to Q3 [31][19] - DAWNZERA achieved $8 million in product sales during its initial months of launch [31] - Olezarsen is projected to exceed $2 billion in peak annual sales, reflecting strong prescriber demand and positive Phase 3 data [24][66] Market Data and Key Metrics Changes - The U.S. market for severe hypertriglyceridemia (sHTG) is significant, with over 1 million individuals affected [22] - The payer mix for TRYNGOLZA is approximately 60% commercial and 40% government, with strong access for both clinically diagnosed and genetically confirmed patients [21] Company Strategy and Development Direction - Ionis aims to achieve cash flow breakeven by 2028, with a focus on launching multiple medicines and advancing its high-value pipeline [39] - The company is preparing for the anticipated launch of Olezarsen for sHTG and expects to leverage its strong relationships with the neurology community for zilganersen [28][29] - Ionis is committed to maximizing the potential of its marketed medicines while preparing for additional launches in 2026 [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver transformational medicines and create shareholder value, citing strong commercial momentum and a robust pipeline [42] - The anticipated approval of Olezarsen is expected to drive significant revenue growth, with management actively engaging with payers to ensure broad access [48][49] Other Important Information - The company has a diversified revenue stream that mitigates risk and enhances financial flexibility [30] - Ionis is on track for three additional launches in 2026, including its first in a broad patient population [42] Q&A Session Summary Question: Guidance on sHTG sales and pricing dynamics - Management clarified that current guidance assumes standard review for Olezarsen, with sales from TRYNGOLZA expected until the sHTG launch [46][47] Question: Reimbursement in FCS and pricing dynamics - Management noted strong patient demand for TRYNGOLZA and ongoing discussions with payers to maximize access while balancing pricing [56][57] Question: Peak sales expectations for Olezarsen - Management increased confidence in the $2 billion peak sales estimate based on strong product profile and prescriber demand research [63][66] Question: FDA interactions regarding sHTG filing - Management indicated that interactions with the FDA have been positive, and they believe Olezarsen deserves priority review [70][72] Question: European sites for Angelman syndrome program - Management confirmed plans to open European sites pending approval from regulators [81][82]

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]

Industry Overview - The drug and biotech sector regained momentum in the latter part of 2025 after a weak first half, setting the stage for a strong year for select stocks [1] - Improved policy clarity following drug pricing agreements with the Trump administration reduced uncertainty, while a rebound in mergers and acquisitions revived investor appetite for risk [1] - Innovation accelerated across high-growth areas such as obesity, gene therapy, inflammation, and neuroscience, with the FDA approving 43 novel therapies as of December 22, 2025 [2] Company Highlights Ionis Pharmaceuticals - Ionis Pharmaceuticals' shares surged 127.6% in 2025, significantly outperforming the industry growth of 5% [5][6] - The company advanced its wholly-owned portfolio, highlighted by the FDA approval of Tryngolza for familial chylomicronemia syndrome, generating $57.4 million in sales in the first nine months of 2025 [9] - Ionis is evaluating Tryngolza in late-stage studies for severe hypertriglyceridemia, with plans to file for FDA label expansion soon [10] - The FDA approved Ionis' second drug, Dawnzera, for hereditary angioedema, with a regulatory filing in the EU expected in early 2026 [11] Structure Therapeutics - Structure Therapeutics' shares surged 127.2% in the past year, compared to the industry's 15.6% growth [13] - The stock rally was driven by positive data from the ACCESS clinical program for aleniglipron, showing up to 15.3% placebo-adjusted weight loss [15][16] - The company plans to initiate phase III development for aleniglipron in mid-2026 and is also developing other candidates for obesity treatment [18] Monopar Therapeutics - Monopar Therapeutics' shares rallied 185.9% in the past year, significantly outperforming the industry [20] - The stock price increase was fueled by positive expectations regarding its lead candidate ALXN-1840 for Wilson disease, following a licensing agreement with AstraZeneca [22] - Monopar plans to submit a regulatory filing with the FDA in early 2026 based on favorable long-term data for ALXN-1840 [26] Kodiak Sciences - Kodiak Sciences' shares rallied 181.1% in the past year, contrasting with the industry's 15.7% decline [27] - The stock's performance reflects growing investor confidence in its late-stage pipeline assets, particularly tarcocimab and KSI-501 [29] - Kodiak plans to submit a regulatory filing for tarcocimab for multiple indications, with top-line data from pivotal studies expected in 2026 [31][33]

Core Points - Ionis Pharmaceuticals has received Breakthrough Therapy designation from the U.S. FDA for zilganersen, aimed at treating Alexander disease, a rare and often fatal neurological condition [1][2] - The company plans to submit a new drug application (NDA) in Q1 2026 [1][3] Company Overview - Ionis Pharmaceuticals is recognized for its innovative approach in developing treatments for serious diseases, including neurological conditions [3][9] - The company has a strong pipeline, including marketed medicines and investigational therapies, positioning it for revenue growth and value creation [3][9] Zilganersen Study Details - The pivotal study for zilganersen involved 54 participants aged 1.5 to 53 years across 13 sites in eight countries, primarily focusing on children due to the early onset of Alexander disease [4][5] - The study demonstrated a statistically significant improvement in gait speed, with a mean difference of 33.3% (p=0.0412) at week 61 for the 50 mg dose compared to control [2][5] Alexander Disease (AxD) Insights - Alexander disease affects approximately 1 in 1 to 3 million people globally and is characterized by progressive neurological deterioration, leading to loss of mobility and independence [7] - There are currently no approved disease-modifying treatments for Alexander disease, highlighting the significance of zilganersen's potential [7][6]